Competing interests
M.C.G.—Speaker fees: Novartis, Knight Therapeutics, GSK, AstraZeneca, Abbvie, Daiichi Sankyo; financial support for educational programs and symposia: Pfizer, Abbvie, GSK, AstraZeneca. R.C.B.—Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Nestle Health Science, Addium, Gilead, MSD, BMS, AstraZeneca, Ache, Pfizer, Roche, Libbs, Lilly, Novartis, and GSK; financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, MSD, Roche, and Novartis; institutional research grants: Novartis, AstraZeneca, Gilead. RBS- Speaker fees and/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Gilead, Libbs, Pfizer, Novartis, MSD, and Roche. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, Gilead, Eli Lilly, and MSD. Institutional research grant: AstraZeneca, Daiichi-Sankyo. D.L.P.M.—No conflicts of interest. B.M.S.P.—No conflicts of interest. K.K.R.—No conflicts of interest. M.K.—No conflicts of interest. U.K.—No conflicts of interest. M.L.—Consulting activities: AstraZeneca, Daiichi-Sankyo, Novartis, Lilly, Gilead and Menarini. A.K.—Principal investigator on funded clinical trials grants: BMS, AstraZeneca, MSD/ Merck.